ASCO is one of the most important weeks of the year for biotech investors. Clinical updates presented during the meeting can rapidly reshape company narratives, regulatory expectations, partnership interest, and valuation outlooks, especially for small and mid-cap oncology companies. Using BPIQ MCP, we screened for companies where ASCO 2026 presentations could represent meaningful inflection points. The final list includes pivotal Phase 3 datasets, late-stage regulatory setup